NovoCure Ltd — Director's Dealing 2019

May 10, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-05-08

Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-09	Ordinary Shares	S	31460	$47.374	Disposed	896463	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-08	Options to Buy Ordinary Shares	$47.56	A	115060	Acquired	2029-05-08	Ordinary Shares (115060)	Direct
2019-05-08	Options to Buy Ordinary Shares	$47.56	A	35000	Acquired	2029-05-08	Ordinary Shares (35000)	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: Options to buy 115,060 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 8, 2022.

F3: Options to buy 35,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 8, 2022.